Identification of CD318 (CDCP1) as novel prognostic marker in AML.

Ann Hematol · 2020 · PMC7060168 · PMID 31965270

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

These findings were supported by analysis of the subgroup of AML patients receiving hypomethylating agents ( n = 13), which showed a clear trend to better OS in CD318 hi cases, however without reaching statistical significance (HR 3.81; p = 0.11) (Fig. 2c ).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.